Literature DB >> 19193751

Late endovascular revascularization in acute ischemic stroke based on clinical-diffusion mismatch.

N Janjua1, A El-Gengaihy, J Pile-Spellman, A I Qureshi.   

Abstract

BACKGROUND AND
PURPOSE: A clinical-diffusion mismatch (CDM) among stroke patients presenting within 12-24 hours has been correlated with neurologic deterioration and infarct expansion. We sought to study the feasibility and safety of reperfusion therapy in a series of 11 consecutive patients fulfilling this criterion.
MATERIALS AND METHODS: Patients presenting with large vessel syndromes were considered for revascularization therapy. Of these patients, we identified those presenting beyond 8 hours who scored > or =8 on the National Institutes of Health Stroke Scale (NIHSS) and had limited abnormalities on diffusion-weighted MR imaging. One- and 7-day NIHSS scores were obtained. Rates of early neurologic deterioration (END, increase in NIHSS score by > or =4 points) and early neurologic improvement (ENI, decrease in NIHSS score by > or =4 points) at 1 week were determined. Follow-up imaging was obtained to evaluate intracranial hemorrhage (ICH).
RESULTS: Eleven patients were identified, 8 of whom were successfully revascularized. The mean age of all patients was 55 years with mean initial, 24-hour, and 1-week NIHSS scores of 14 +/- 4, 11 +/- 7, and 6 +/- 5, respectively, with lower scores at 24 hours and 1 week (8 +/- 5 and 4 +/- 3, respectively) among patients successfully revascularized. Eight of the treated patients (72% of the total, 100% of those successfully revascularized) experienced ENI. No patient had END or ICH.
CONCLUSIONS: Endovascular treatment for acute ischemic stroke beyond 8 hours is feasible and may prevent END and promote ENI in patients fulfilling the criteria of a CDM. A prospective study is planned.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19193751      PMCID: PMC7051658          DOI: 10.3174/ajnr.A1474

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  21 in total

1.  Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Authors:  A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

2.  Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison.

Authors:  Julio A Chalela; Chelsea S Kidwell; Lauren M Nentwich; Marie Luby; John A Butman; Andrew M Demchuk; Michael D Hill; Nicholas Patronas; Lawrence Latour; Steven Warach
Journal:  Lancet       Date:  2007-01-27       Impact factor: 79.321

3.  Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score.

Authors:  P A Barber; A M Demchuk; J Zhang; A M Buchan
Journal:  Lancet       Date:  2000-05-13       Impact factor: 79.321

4.  Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset.

Authors:  Anthony J Furlan; Dirk Eyding; Gregory W Albers; Yasir Al-Rawi; Kennedy R Lees; Howard A Rowley; Christian Sachara; Mariola Soehngen; Steven Warach; Werner Hacke
Journal:  Stroke       Date:  2006-03-30       Impact factor: 7.914

5.  Clinical-diffusion mismatch predicts the putative penumbra with high specificity.

Authors:  Jane Prosser; Ken Butcher; Louise Allport; Mark Parsons; Lachlan MacGregor; Patricia Desmond; Brian Tress; Stephen Davis
Journal:  Stroke       Date:  2005-07-14       Impact factor: 7.914

6.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

Authors:  J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

7.  Comparison of diffusion-weighted MRI and CT in acute stroke.

Authors:  M G Lansberg; G W Albers; C Beaulieu; M P Marks
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

8.  MERCI 1: a phase 1 study of Mechanical Embolus Removal in Cerebral Ischemia.

Authors:  Y Pierre Gobin; Sidney Starkman; Gary R Duckwiler; Thomas Grobelny; Chelsea S Kidwell; Reza Jahan; John Pile-Spellman; Alan Segal; Fernando Vinuela; Jeffrey L Saver
Journal:  Stroke       Date:  2004-10-28       Impact factor: 7.914

9.  Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial.

Authors:  Wade S Smith; Gene Sung; Jeffrey Saver; Ronald Budzik; Gary Duckwiler; David S Liebeskind; Helmi L Lutsep; Marilyn M Rymer; Randall T Higashida; Sidney Starkman; Y Pierre Gobin; Donald Frei; Thomas Grobelny; Frank Hellinger; Dan Huddle; Chelsea Kidwell; Walter Koroshetz; Michael Marks; Gary Nesbit; Isaac E Silverman
Journal:  Stroke       Date:  2008-02-28       Impact factor: 7.914

10.  Clinical-diffusion mismatch defined by NIHSS and ASPECTS in non-lacunar anterior circulation infarction.

Authors:  H Tei; S Uchiyama; T Usui
Journal:  J Neurol       Date:  2007-03-07       Impact factor: 4.849

View more
  4 in total

1.  Thrombectomy for delayed basilar stent occlusion with good outcome.

Authors:  Nazli Janjua; Jeffrey Farkas
Journal:  J Vasc Interv Neurol       Date:  2013-12

Review 2.  Evolution of the stroke paradigm: A review of delayed recanalization.

Authors:  Richard Camara; Nathanael Matei; John H Zhang
Journal:  J Cereb Blood Flow Metab       Date:  2020-12-16       Impact factor: 6.200

3.  Mechanically assisted intra-arterial thrombolysis in acute cerebral infarction.

Authors:  Hui-Xiao Wang; Yi-Jin Shen; Shu-Jun Ye; Yong-Kang Xu; Jian-Pin Zhang; Zhou Lu
Journal:  Exp Ther Med       Date:  2013-03-06       Impact factor: 2.447

4.  Interleukin-10 facilitates the selection of patients for systemic thrombolysis.

Authors:  Manuel Rodríguez-Yáñez; Mar Castellanos; Tomás Sobrino; David Brea; Pedro Ramos-Cabrer; Salvador Pedraza; José A Castiñeiras; Joaquín Serena; Antonio Dávalos; José Castillo; Miguel Blanco
Journal:  BMC Neurol       Date:  2013-06-17       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.